Kura Oncology Inc
↗San Diego, California, USA
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Through their evolving understanding of the molecular processes that drive cancer, Kura is pioneering new approaches to treat devastating diseases, including acute myeloid leukemia (AML), head and neck cancer, and other hematologic malignancies. The company's small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment, employing precision oncology approaches based on specific genetic mutations.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$0M (Pre-revenue, clinical-stage)
Founded:2014
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$63.4M
Investors:Avoro Capital Advisors, Foresite Capital, EcoR1 Capital, Suvretta Capital Management, Bristol-Myers Squibb, Arch Venture Partners, Hercules Capital
STOCK
Exchange:NASDAQ
Ticker:KURA
Market Cap:$710M-$904M
PIPELINE
Stage:Phase 1|Phase 2|Phase 3|Approved
Lead Drug Stage:FDA Approved (Ziftomenib/KOMZIFTI)
Modalities:Small molecule, Menin inhibitor, Farnesyl transferase inhibitor (FTI)
Active Trials:5
Trial Phases:Phase 1: 2 | Phase 2: 1 | Phase 3: 2
FDA Approvals:1
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Kyowa Kirin Co., Ltd. - Global strategic collaboration for development and commercialization of ziftomenib in AML and hematologic malignancies (announced November 2024)
COMPETITION
Position:Emerging Leader
Competitors:Syndax Pharmaceuticals, Biomea Fusion, DiaCarta, Mission Bio, Quadrants Scientific, Xenetic Bioscience, NexImmune, Inovio Pharmaceuticals +2 more
LEADERSHIP
Key Executives:
Troy E. Wilson, Ph.D., J.D. - President, CEO and Chairman
Marc Grasso, M.D. - Chief Financial Officer and Chief Business Officer
Kathleen Ford - Chief Operating Officer
Mollie Leoni, M.D. - Chief Medical Officer
Francis Burrows, Ph.D. - Chief Scientific Officer
Scientific Founders:Troy E. Wilson, Ph.D., J.D., Kevan M. Shokat, Ph.D. (UCSF Professor)
Board Members:Troy E. Wilson, Ph.D., J.D. (Chairman, President, CEO), Carol Schafer (Joined 2021; 25+ years healthcare investment banking experience), Mary Szela (Joined 2018; 30+ years biotech/pharma executive experience; CEO of TriSalus Life Sciences), Diane Parks (Joined 2019; 30+ years pharma/biotech commercial experience), Helen Collins, M.D., Michael Vasconcelles, M.D. (Joined 2024; 25+ years oncology drug development experience)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kura Oncology Inc. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.